Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Among authors: morant r. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, Smyth JF, Morant R, de Vries MJ, Roelvink M, Fumoleau P; European Organization for Research and Treatment of Cancer (EORTC). Coudert B, et al. Among authors: morant r. Eur J Cancer. 2001 Nov;37(17):2194-8. doi: 10.1016/s0959-8049(01)00286-6. Eur J Cancer. 2001. PMID: 11677106 Clinical Trial.
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D, Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M. Steinbild S, et al. Among authors: morant r. Br J Cancer. 2007 Dec 3;97(11):1480-5. doi: 10.1038/sj.bjc.6604064. Epub 2007 Nov 27. Br J Cancer. 2007. PMID: 18040273 Free PMC article. Clinical Trial.
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M. Jermann M, et al. Among authors: morant r. Cancer Chemother Pharmacol. 2006 Apr;57(4):533-9. doi: 10.1007/s00280-005-0070-z. Epub 2005 Jul 29. Cancer Chemother Pharmacol. 2006. PMID: 16052341 Free article. Clinical Trial.
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, Pagani O, Leyvraz S, Morant R, Pestalozzi B, Hanselmann S, Goldhirsch A. Borner MM, et al. Among authors: morant r. Ann Oncol. 1998 May;9(5):535-41. doi: 10.1023/a:1008270916325. Ann Oncol. 1998. PMID: 9653495 Free article. Clinical Trial.
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.
Schmid HP, Maibach R, Bernhard J, Hering F, Hanselmann S, Gusset H, Morant R, Pestalozzi D, Castiglione M. Schmid HP, et al. Among authors: morant r. Cancer. 1997 May 1;79(9):1703-9. doi: 10.1002/(sici)1097-0142(19970501)79:9<1703::aid-cncr10>3.0.co;2-1. Cancer. 1997. PMID: 9128985 Clinical Trial.
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD. Borner MM, et al. Among authors: morant r. J Clin Oncol. 2002 Apr 1;20(7):1759-66. doi: 10.1200/JCO.2002.07.087. J Clin Oncol. 2002. PMID: 11919232 Clinical Trial.
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Van Cutsem E, Dirix L, Van Laethem JL, Van Belle S, Borner M, Gonzalez Baron M, Roth A, Morant R, Joosens E, Gruia G, Sibaud D, Bleiberg H. Van Cutsem E, et al. Among authors: morant r. Br J Cancer. 2005 Mar 28;92(6):1055-62. doi: 10.1038/sj.bjc.6602462. Br J Cancer. 2005. PMID: 15756271 Free PMC article. Clinical Trial.
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H. Thatcher N, et al. Among authors: morant r. Br J Cancer. 1999 May;80(3-4):396-402. doi: 10.1038/sj.bjc.6690369. Br J Cancer. 1999. PMID: 10408844 Free PMC article. Clinical Trial.
107 results